Barrington Research Maintains Outperform on Haemonetics, Raises Price Target to $140
Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform and raises the price target from $118 to $140.
Stocks · News reference
8-K filing — HAEMONETICS CORP (HAE)
Filed: 2026-10-08 AccNo: 0000313143-26-000138 Size: 143 KB Item 7.01: Regulation FD Disclosure
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Mizuho Maintains Outperform on Haemonetics, Raises Price Target to $140
Mizuho analyst Anthony Petrone maintains Haemonetics (NYSE:HAE) with a Outperform and raises the price target from $95 to $140.
Haemonetics shares are trading higher after BTIG maintained its Buy rating on the stock and raised its price target from $110 to $130.
BTIG Maintains Buy on Haemonetics, Raises Price Target to $130